Dental Health

U.S. FDA lifts clinical hold on new treatment for prevention of dental caries

Published in Medical Letter on the CDC and FDA, January 2nd, 2005

Oragenics, Inc., (ONI) reported that the U.S. Food and Drug Administration (FDA) has agreed to lift the clinical hold on the company's Replacement Therapy for the treatment of dental caries.

The FDA's clearance to proceed with a phase I safety trial came following the agency's completed review of the study's clinical design and the unanimous vote of the Recombinant DNA Advisory Committee on March 15, 2004, that the first human clinical study of Oragenics' Replacement Therapy be carried out under the protocol proposed by the company. The FDA had placed Oragenics' original investigational new drug application on clinical hold in May 2003, pending further review of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-01-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry